The assessment of disease severity in ulcerative colitis depends mainly on subjective variables, and an objective method of assessing mucosal inflammation is needed. Determination of the synthetic phase of the cell cycle is an accurate expression of inflammatory activity in the colonic mucosa. The aim of the study was to find out if the proliferative index or the synthetic phase (S phase) of the colonic mucosa of patients with ulcerative colitis, as evaluated by DNA flow cytometry, is a reliable and reproducible marker of disease activity. Sixty consecutive patients with ulcerative colitis of different degrees of activity were entered into the study and submitted to colonoscopy plus multiple rectal biopsies. Disease severity was defined for each patient by means of a clinical, endoscopic, and histological score. Flow cytometry was used to calculate the proliferative index and the S phase of the cell cycle. A statistically significant correlation (p<0.001) was found between all indices of severity. It is suggested that flow cytometric evaluation of the cell cycle in the rectal mucosa may be an efficient method of assessing severity of disease and efficacy of medical treatment in ulcerative colitis.
Abstract
The assessment of disease severity in ulcerative colitis depends mainly on subjective variables, and an objective method of assessing mucosal inflammation is needed. Determination of the synthetic phase of the cell cycle is an accurate expression of inflammatory activity in the colonic mucosa. The aim of the study was to find out if the proliferative index or the synthetic phase (S phase) of the colonic mucosa of patients with ulcerative colitis, as evaluated by DNA flow cytometry, is a reliable and reproducible marker of disease activity. Sixty consecutive patients with ulcerative colitis of different degrees of activity were entered into the study and submitted to colonoscopy plus multiple rectal biopsies. Disease with ulcerative colitis of different degrees of activity and receiving different treatment courses were entered into the study. The patients participated in a precancerous surveillance protocol based on histological examination and flow cytometry, irrespective of duration of illness. Each patient was submitted to diagnostic colonoscopy, and mucosal biopsy specimens were taken by biopsy forceps at various anatomical sites in the colon (caecum, ascending colon, hepatic flexure, transverse colon, splenic flexure, descending colon, sigmoid colon, and rectum). Twenty non-consecutive patients complaining of active ulcerative colitis were also submitted to a subsequent endoscopic examination after a course of medical treatment. For the purposes of this study we considered only the most distal rectal biopsy specimens: a couple of samples were taken in the rectum from adjacent sites of the mucosa. One sample from each pair was fixed in Bouin's solution for histological examination and the other immediately put in saline and submitted to flow cytometric analysis. At the same time we scored clinical and endoscopic severity of disease.
Clinical activity was determined using a semi-quantitative index, according to Rachmilewitz, 5 ESR=erythrocyte sedimentation rate, Hb=haemoglobin.
in the lamina propria, 3 as crypt abscess formation and inflammation in the lamina propria, 4 as more severe inflammation with destructive crypt abscesses plus or minus granulomata, and 5 as severe inflammation with active ulceration. No patient had granulomata and the diagnosis of ulcerative colitis, excluding other inflammatory diseases, was histologically confirmed in all patients.
Tissue samples for flow cytometric analysis were submitted to mechanical disintegration and fixed in 70% ethanol for 25 minutes, after which the cells were suspended in phosphate buffered saline buffer and centrifuged at 1200 rpm. Cells were resuspended and counted at optical microscopy, with an optimal value of 500 000/1 000 000 cells/ml. The monolayer cells were then resuspended in a propidium iodide (50 mcg/ml, Sigma Chemicals), 01% dibasic sodium citrate, 0O1% NONIDET NP40, and RNAse (0 5 ng/ml, 100 U, Sigma Chemical) solution, and incubated in the dark for 30 minutes. The suspension was then filtered through 50 CVs higher than 3% for test spheres or nuclei suggest that the apparatus requires adjustment: the instrument is ready for analysis of test samples when a low, reproducible CV is obtained for the control material. Coefficients of variation of DNA distributions from actual samples are typically higher than CVs of distributions from standards.8 9 For statistical analysis we used the two tailed correlation test, analysis of variance, and regression analysis. The study complied with the standards of the ethical committee of our institution.
Results

CLINICAL ACTIVITY
The clinical assessment of illness activity varies from 1 to 9 according to the above mentioned score. For statistical evaluation we grouped the patients in grade 1 (score 1, 17 patients, 28.3%), grade 2 (scores 2-3, 19 patients, 31 .6%), grade 3 (scores 4-5, 11 patients, 18-4%), and grade 4 (scores 6-9, 13 patients, 21 .6%)/ HISTOLOGICAL ACTIVITY Three patients (5%) were grade 1, 27 (45%) grade 2, 21 (35%) grade 3, and 9 (15%) grade 4 of histological activity. We considered separately for statistical evaluation both the synthetic phase of the cell cycle alone and the so called proliferative index (the sum of the S and G2+M phases of the cycle):
the reported values were divided into quartiles and then submitted to analysis. S phase values ranged from 4 to 29% and the proliferative index from 10 to 38% (Figs 3 and 4) .
CORRELATION TESTS
The above mentioned variables were inserted in a two tailed correlation test: we noticed a significant (p<0 001) correlation between all the illness severity assessment methods considered (Table II) . We also analysed the correlation between the proliferative index and the clinical, histological, and endoscopic scores calculated as a whole: a significant correlation was found (p<0-001) with an overall x2 value of 27X6 with 8 degrees of freedom. We also did the regression analysis for the mean difference in proliferative index versus global score (endoscopy plus histology plus clinical index) in the 20 patients we analysed before and after a therapeutic course with mesalazine 3.6 g orally. Figure 5 shows that a close correlation was detected with a coefficient of correlation r of 0 7 1.
Discussion
The gold standard in the routine clinical assessment of ulcerative colitis is the three step grading system by Truelove and Witts. 1 This is easy to use and makes good clinical sense, but it is not wholly reliable in controlled clinical trials.
There is a critical need for a more quantitative and reproducible index for planning the management and evaluating the treatment. Several such clinical indices have been proposed, aimed at providing a numerical activity score. The Powell-Tuck activity score10 has been used in several clinical trials, but it relies heavily on symptoms and signs. Gomes et al 6 devised a similar scoring system and compared it with endoscopic and histological findings, but, unfortunately, failed to establish any statistically significant correlation. with a good coefficient of correlation r.
The advantage of DNA flow cytometry on the conventional tests is mainly in its accuracy, low inter and intraobserver variability, and reproducibility of data. It analyses a much greater number of cells (about 10 000 v 300) in a much shorter period of time (few seconds v roughly 15 minutes) than a routine histological examination. On the other hand, it gives only quantitative and not qualitative data. We therefore suggest its use in controlled trials to obtain reproducible and comparable results, and currently as a complement to routine histological tests in clinical use: problems of costs and availability of the flow cytometer may in fact limit its use in a number of institutions.
In conclusion, we suggest that DNA flow cytometry, in addition to providing information on DNA aneuploidy as a precancerous lesion, may also afford a reproducible and efficient method for evaluating severity of disease and efficacy of medical treatment in ulcerative colitis. 
